US5824307A
(en)
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US20070202127A1
(en)
*
|
1993-06-07 |
2007-08-30 |
Duke University |
Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
|
US6479055B1
(en)
*
|
1993-06-07 |
2002-11-12 |
Trimeris, Inc. |
Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
|
FR2719593B1
(fr)
*
|
1994-05-06 |
1996-05-31 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US20030198640A1
(en)
*
|
1994-11-07 |
2003-10-23 |
Human Genome Sciences, Inc. |
Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US6410008B1
(en)
|
1994-12-12 |
2002-06-25 |
Beth Israel Hospital Association |
Chimeric IL-10 proteins and uses thereof
|
JPH11501506A
(ja)
*
|
1994-12-12 |
1999-02-09 |
ベス イスラエル デアコネス メディカル センター |
キメラ型サイトカインおよびその利用
|
GB9526733D0
(en)
*
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
US6423512B1
(en)
|
1996-07-26 |
2002-07-23 |
Novartis Ag |
Fusion polypeptides
|
US7285267B2
(en)
*
|
1997-01-14 |
2007-10-23 |
Human Genome Sciences, Inc. |
Tumor necrosis factor receptors 6α & 6β
|
US20040013664A1
(en)
*
|
1997-01-14 |
2004-01-22 |
Gentz Reiner L. |
Tumor necrosis factor receptors 6 alpha & 6 beta
|
AT406373B
(de)
|
1997-02-27 |
2000-04-25 |
Immuno Ag |
Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
|
AT405403B
(de)
|
1997-02-27 |
1999-08-25 |
Immuno Ag |
Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
|
KR20010020342A
(ko)
|
1997-04-28 |
2001-03-15 |
자끄 사비나 |
종양치료용 맥관형성 길항제의 아데노바이러스-매개 종양내 전달방법
|
AT408443B
(de)
*
|
1998-02-27 |
2001-11-26 |
Immuno Ag |
Verfahren zur gewinnung von gereinigtem faktor viii:c/vwf-komplex
|
US6656906B1
(en)
|
1998-05-20 |
2003-12-02 |
Trimeris, Inc. |
Hybrid polypeptides with enhanced pharmacokinetic properties
|
US6605222B1
(en)
*
|
1998-05-20 |
2003-08-12 |
Baxter Aktiengesellschaft |
Method for producing a factor VIII/von Willebrand factor complex
|
JP4087563B2
(ja)
*
|
1998-06-15 |
2008-05-21 |
ジーティーシー バイオセラピューティックス インコーポレイテッド |
エリスロポエチン類似体−ヒト血清アルブミン融合物
|
US20050181482A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Meade Harry M. |
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
|
US20030215359A1
(en)
*
|
1998-10-02 |
2003-11-20 |
Ischemia Technologies, Inc. |
Tests for the rapid evaluation of ischemic states and kits
|
US7449338B2
(en)
|
1998-10-02 |
2008-11-11 |
Ischemia Technologies, Inc. |
Tests for the rapid evaluation of ischemic states and kits
|
US20050142613A1
(en)
*
|
1998-10-02 |
2005-06-30 |
David Bar-Or |
Test for the rapid evaluation of ischemic states and kits
|
US7070937B1
(en)
|
1998-10-02 |
2006-07-04 |
Ischemia Technologies, Inc. |
Marker useful for detection and measurement of free radical damage and method
|
US7297544B2
(en)
*
|
1998-10-02 |
2007-11-20 |
Ischemia Technologies, Inc. |
Tests for the rapid evaluation of ischemic states and kits
|
US6475743B1
(en)
*
|
1998-10-02 |
2002-11-05 |
Ischemia Technologies, Inc. |
Marker useful for detection and measurement of free radical damage and method
|
US20030190740A1
(en)
|
1998-10-13 |
2003-10-09 |
The University Of Georgia Research Foundation, Inc |
Stabilized bioactive peptides and methods of identification, synthesis, and use
|
GB9824632D0
(en)
*
|
1998-11-10 |
1999-01-06 |
Celltech Therapeutics Ltd |
Biological compounds
|
DE60043021D1
(de)
*
|
1999-05-17 |
2009-11-05 |
Conjuchem Biotechnologies Inc |
Lang wirkende Peptidinhibitoren der Virusfusion mit Körperzellen bei viralen Infektionen
|
US7601691B2
(en)
*
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
US20040266673A1
(en)
*
|
2002-07-31 |
2004-12-30 |
Peter Bakis |
Long lasting natriuretic peptide derivatives
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
US6951738B2
(en)
*
|
1999-07-16 |
2005-10-04 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptors TR13 and TR14
|
US20020048571A1
(en)
*
|
1999-07-19 |
2002-04-25 |
Jeno Gyuris |
Chimeric polypeptides of serum albumin and uses related thereto
|
US6797695B1
(en)
*
|
1999-10-22 |
2004-09-28 |
Kyoto University |
Human FGF-20 gene and gene expression products
|
US6716626B1
(en)
*
|
1999-11-18 |
2004-04-06 |
Chiron Corporation |
Human FGF-21 nucleic acids
|
EP1232264B1
(de)
|
1999-11-18 |
2009-10-21 |
Novartis Vaccines and Diagnostics, Inc. |
Menschliches fgf-21 gen und genexpressionsprodukte
|
US6849257B2
(en)
*
|
2000-02-04 |
2005-02-01 |
Children's Hospital Research Foundation |
Lipid hydrolysis therapy for atherosclerosis and related diseases
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1274720A4
(de)
|
2000-04-12 |
2004-08-18 |
Human Genome Sciences Inc |
Albumin enthaltende fusionsproteine
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP2431054A3
(de)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Menschlicher Tumornekrosefaktor Delta und Ypsilon
|
AU6842701A
(en)
|
2000-06-16 |
2002-01-14 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
WO2002007762A1
(en)
*
|
2000-07-24 |
2002-01-31 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptors tr21 and tr22
|
WO2002018622A2
(en)
*
|
2000-08-25 |
2002-03-07 |
Human Genome Sciences, Inc. |
TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
|
PL393178A1
(pl)
*
|
2000-12-07 |
2011-02-14 |
Eli Lilly And Company |
Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulino-niezależną i kompozycja farmaceutyczna do leczenia pacjentów z otyłością
|
JP2005503116A
(ja)
|
2001-02-09 |
2005-02-03 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトgタンパク質ケモカインレセプター(ccr5)hdgnr10
|
WO2002074806A2
(en)
|
2001-02-27 |
2002-09-26 |
Maxygen Aps |
New interferon beta-like molecules
|
FR2822834B1
(fr)
*
|
2001-04-02 |
2005-02-25 |
Flamel Tech Sa |
Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
|
EP1372707A1
(de)
*
|
2001-04-06 |
2004-01-02 |
Institut Pasteur |
Lipopolysaccharid-konjugierte impfstoff zur behandlung von cholera
|
US6887462B2
(en)
|
2001-04-09 |
2005-05-03 |
Chiron Corporation |
HSA-free formulations of interferon-beta
|
US20060084794A1
(en)
*
|
2001-04-12 |
2006-04-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050244931A1
(en)
*
|
2001-04-12 |
2005-11-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7507413B2
(en)
|
2001-04-12 |
2009-03-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050054051A1
(en)
*
|
2001-04-12 |
2005-03-10 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
ATE470676T1
(de)
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
Anti-vegf-2 antikörper
|
CA2446739A1
(en)
*
|
2001-05-25 |
2002-12-05 |
Human Genome Sciences, Inc. |
Chemokine beta-1 fusion proteins
|
CN100594935C
(zh)
|
2001-05-25 |
2010-03-24 |
人体基因组科学有限公司 |
免疫特异性结合trail受体的抗体
|
ATE295370T1
(de)
*
|
2001-05-31 |
2005-05-15 |
Conjuchem Inc |
Langwirkende fusionspeptid-inhibitoren für hiv- infektion
|
WO2003018611A2
(en)
|
2001-08-24 |
2003-03-06 |
University Of Victoria Innovation And Development Corporation |
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
|
US7176278B2
(en)
*
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
WO2003020746A1
(en)
*
|
2001-08-30 |
2003-03-13 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
US20070031440A1
(en)
*
|
2001-08-30 |
2007-02-08 |
Prior Christopher P |
Modified transferin-antibody fusion proteins
|
US20030226155A1
(en)
*
|
2001-08-30 |
2003-12-04 |
Biorexis Pharmaceutical Corporation |
Modified transferrin-antibody fusion proteins
|
US20030228298A1
(en)
*
|
2001-09-04 |
2003-12-11 |
Mark Nesbit |
Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
|
US6797493B2
(en)
*
|
2001-10-01 |
2004-09-28 |
Lee-Hwei K. Sun |
Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
|
WO2003030821A2
(en)
*
|
2001-10-05 |
2003-04-17 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7737260B2
(en)
|
2003-11-13 |
2010-06-15 |
Hanmi Pharm. Co., Ltd |
Protein complex using an immunoglobulin fragment and method for the preparation thereof
|
US20080167238A1
(en)
*
|
2001-12-21 |
2008-07-10 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
CA2484556A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
KR101271635B1
(ko)
*
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
CA2841097A1
(en)
*
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin and g-csf fusion proteins
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
KR100441384B1
(ko)
*
|
2002-01-08 |
2004-07-21 |
주식회사 안지오랩 |
인간 혈청 알부민-팀프-2 융합 단백질 발현시스템 및재조합 인간 혈청 알부민-팀프-2 융합 단백질
|
US20060046249A1
(en)
*
|
2002-01-18 |
2006-03-02 |
Fei Huang |
Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways
|
US20060241027A1
(en)
*
|
2002-02-07 |
2006-10-26 |
Hans-Peter Hauser |
Hiv inhibiting proteins
|
US20050222023A1
(en)
*
|
2002-02-07 |
2005-10-06 |
Hans-Peter Hauser |
Albumin-fused kunitz domain peptides
|
NZ579419A
(en)
*
|
2002-02-07 |
2011-02-25 |
Dyax Corp |
Albumin-fused kunitz domain peptides
|
CA2480052A1
(en)
*
|
2002-04-01 |
2003-10-16 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
EP1499352A4
(de)
|
2002-04-12 |
2006-10-11 |
Medimmune Inc |
Rekombinante anti-interleukin-9-antikörper
|
PL208998B1
(pl)
*
|
2002-04-23 |
2011-07-29 |
Cargill |
Sposób wytwarzania monatyny
|
FR2840614B1
(fr)
|
2002-06-07 |
2004-08-27 |
Flamel Tech Sa |
Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
|
EP1837031B1
(de)
*
|
2002-06-07 |
2009-10-14 |
Waratah Pharmaceuticals, Inc. |
Methoden und Kompositionen um Diabetes zu behandeln
|
AU2003274463B2
(en)
*
|
2002-06-10 |
2009-10-29 |
University Of Rochester |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US20040059093A1
(en)
*
|
2002-07-16 |
2004-03-25 |
Stuart Bussell |
Methods to construct multimeric DNA and polymeric protein sequences as direct fusions or with linkers
|
FR2843117B1
(fr)
*
|
2002-07-30 |
2004-10-15 |
Flamel Tech Sa |
Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
|
US20060105387A1
(en)
*
|
2002-08-30 |
2006-05-18 |
Prior Christopher P |
Transferrin fusion proteins libraries
|
WO2004022736A1
(ja)
|
2002-08-30 |
2004-03-18 |
Japan Science And Technology Corporation |
遺伝子のターゲティング破壊法および超耐熱菌ゲノム、ならびにこれらを利用したゲノムチップ
|
DE60333306D1
(de)
*
|
2002-08-30 |
2010-08-19 |
Biorexis Pharmaceutical Corp |
Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
|
US20040052777A1
(en)
*
|
2002-09-04 |
2004-03-18 |
Mark Nesbit |
Kringle polypeptides and methods for using them to inhibit angiogenesis
|
US20040229810A1
(en)
*
|
2002-10-22 |
2004-11-18 |
Antonio Cruz |
Gastrin compositions and formulations, and methods of use and preparation
|
US7553930B2
(en)
*
|
2003-01-06 |
2009-06-30 |
Xencor, Inc. |
BAFF variants and methods thereof
|
US20060014248A1
(en)
*
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
US20050221443A1
(en)
*
|
2003-01-06 |
2005-10-06 |
Xencor, Inc. |
Tumor necrosis factor super family agonists
|
ES2398460T3
(es)
|
2003-02-06 |
2013-03-19 |
Queen's University Of Belfast |
Péptido antagonista del receptor B2 de bradiquinina proveniente de la piel de un anfibio
|
US20070060512A1
(en)
*
|
2003-03-04 |
2007-03-15 |
Homayoun Sadeghi |
Dipeptidyl-peptidase protected protein
|
US7354584B2
(en)
|
2003-04-11 |
2008-04-08 |
Medimmune, Inc. |
Recombinant IL-9 antibodies
|
US20050079546A1
(en)
*
|
2003-05-01 |
2005-04-14 |
Dasa Lipovsek |
Serum albumin scaffold-based proteins and uses thereof
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US20080039379A1
(en)
*
|
2003-05-27 |
2008-02-14 |
Waratah Pharmaceuticals, Inc. |
Compositions Comprising Gastrin Compounds and Their Use in Diabetes
|
FR2855521B1
(fr)
*
|
2003-05-28 |
2005-08-05 |
Flamel Tech Sa |
Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
|
AU2004259727A1
(en)
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of cancer and infectious diseases.
|
JP2007520441A
(ja)
*
|
2003-07-25 |
2007-07-26 |
コンジュシェム,インコーポレイティド |
持続性インスリン誘導体及びその方法
|
US20070275871A1
(en)
*
|
2003-08-28 |
2007-11-29 |
Biorexis Technology, Inc. |
Epo Mimetic Peptides and Fusion Proteins
|
US20060205037A1
(en)
*
|
2003-08-28 |
2006-09-14 |
Homayoun Sadeghi |
Modified transferrin fusion proteins
|
FR2860516B1
(fr)
*
|
2003-10-03 |
2006-01-13 |
Flamel Tech Sa |
Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
|
EP1675871A2
(de)
|
2003-10-10 |
2006-07-05 |
Xencor Inc. |
Tnf-alpha-varianten auf proteinbasis zur behandlung von erkrankungen in verbindung mit tnf-alpha
|
FR2862535B1
(fr)
*
|
2003-11-21 |
2007-11-23 |
Flamel Tech Sa |
Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques
|
FR2862536B1
(fr)
*
|
2003-11-21 |
2007-11-23 |
Flamel Tech Sa |
Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
|
AU2004296184B2
(en)
*
|
2003-12-04 |
2010-12-16 |
Vaccinex, Inc. |
Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
|
WO2005058961A2
(en)
|
2003-12-12 |
2005-06-30 |
Amgen Inc. |
Antibodies specific for human galanin, and uses thereof
|
EP1716165A4
(de)
*
|
2004-01-23 |
2008-06-18 |
Virxsys Corp |
Expression von apoa-1 und varianten davon unter verwendung des spleissosom-vermittelten rna-trans-spleissens
|
BRPI0507026A
(pt)
*
|
2004-02-09 |
2007-04-17 |
Human Genome Sciences Inc |
proteìnas de fusão de albumina
|
WO2005097184A2
(en)
*
|
2004-03-26 |
2005-10-20 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
SG151315A1
(en)
*
|
2004-03-31 |
2009-04-30 |
Centocor Inc |
Human glp-1 mimetibodies, compositions, methods and uses
|
AU2005240680A1
(en)
*
|
2004-05-06 |
2005-11-17 |
Conjuchem Biotechnologies Inc. |
Compounds for specific viral target
|
WO2006012451A2
(en)
|
2004-07-22 |
2006-02-02 |
Five Prime Therapeutics, Inc. |
Compositions and methods of use for mgd-csf in disease treatment
|
EP2292750A3
(de)
|
2004-07-30 |
2011-12-21 |
Novozymes A/S |
Alanine 2, 3 Aminomutasen
|
EP1789096A4
(de)
|
2004-09-07 |
2009-07-08 |
Archemix Corp |
Aptamere für den von-willebrand-faktor und ihre verwendung als therapeutika für thrombotische erkrankungen
|
AU2005282380A1
(en)
*
|
2004-09-07 |
2006-03-16 |
Archemix Corp. |
Aptamer medicinal chemistry
|
US7566701B2
(en)
*
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
AU2005286770A1
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP1799713B1
(de)
|
2004-09-23 |
2014-11-05 |
VasGene Therapeutics, Inc. |
Polypeptidverbindungen zur hemmung von angiogenese und tumorwachstum
|
JP5053850B2
(ja)
*
|
2004-10-08 |
2012-10-24 |
バークシス コーポレーション |
抗体遺伝子導入および抗体ポリペプチド産生のためのrnaトランススプライシングの使用
|
EP1797184B1
(de)
*
|
2004-10-08 |
2012-09-26 |
VIRxSYS Corporation |
Gerichtetes transspleissen von hochabundanten transkripten zur in-vivo-herstellung rekombinanter proteine
|
US8168588B2
(en)
|
2005-01-25 |
2012-05-01 |
Five Prime Therapeutics, Inc. |
Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions
|
AU2006214121B9
(en)
|
2005-02-15 |
2013-02-14 |
Duke University |
Anti-CD19 antibodies and uses in oncology
|
US7723472B2
(en)
*
|
2005-02-28 |
2010-05-25 |
The Regents Of The University Of California |
Extracellular matrix binding chimeric proteins and methods of use thereof
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
US7833979B2
(en)
*
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
UA95446C2
(ru)
*
|
2005-05-04 |
2011-08-10 |
Іллюміджен Байосайєнсіз, Інк. |
Мутаци в генах oas1
|
WO2006121852A2
(en)
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
CN102321174B
(zh)
|
2005-05-06 |
2013-10-16 |
津莫吉尼蒂克斯公司 |
Il-31单克隆抗体及使用方法
|
US20080076729A1
(en)
*
|
2005-05-19 |
2008-03-27 |
Schering Aktiengesellachaft |
Interferon-beta gene therapy using an improved, regulated expression system
|
US20070179113A1
(en)
*
|
2005-05-19 |
2007-08-02 |
Schering Aktiengesellachaft |
GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
|
DOP2006000117A
(es)
*
|
2005-05-19 |
2007-11-30 |
Schering Ag |
Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada
|
TW200724679A
(en)
*
|
2005-05-19 |
2007-07-01 |
Schering Ag |
Treatment of disease using an improved regulated expression system
|
WO2006138700A2
(en)
*
|
2005-06-17 |
2006-12-28 |
Biorexis Pharmaceutical Corporation |
Anchored transferrin fusion protein libraries
|
JP4822371B1
(ja)
|
2005-07-22 |
2011-11-24 |
ファイブ プライム セラピューティクス, インコーポレイテッド |
Fgfr融合タンパク質によって疾患を治療するための組成物および方法
|
PT2573114T
(pt)
|
2005-08-10 |
2016-07-13 |
Macrogenics Inc |
Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
|
JP5905184B2
(ja)
|
2005-10-13 |
2016-04-20 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. |
自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
|
CA2562249A1
(en)
*
|
2005-10-20 |
2007-04-20 |
University Of Ottawa Heart Institute |
Anf analogue
|
US8168592B2
(en)
*
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
JP5401095B2
(ja)
|
2005-11-17 |
2014-01-29 |
ゾゲニクス インコーポレーティッド |
無針注射による粘性製剤の送達方法
|
US20080280328A1
(en)
*
|
2005-11-18 |
2008-11-13 |
Novozymes A/S |
Glucoamylase Variants
|
CN101384272B
(zh)
|
2005-12-20 |
2013-05-01 |
杜克大学 |
用于递送具有增强的药理性质的活性剂的方法和组合物
|
CA2634495A1
(en)
*
|
2005-12-22 |
2007-06-28 |
Conjuchem Biotechnologies Inc. |
Process for the production of preformed conjugates of albumin and a therapeutic agent
|
US7625564B2
(en)
*
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
EP1816201A1
(de)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
|
EP2650306A1
(de)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
JP2009531324A
(ja)
|
2006-03-20 |
2009-09-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
癌標的化のための操作された抗前立腺幹細胞抗原(psca)抗体
|
EP2046367A4
(de)
*
|
2006-06-07 |
2009-11-11 |
Human Genome Sciences Inc |
Albuminfusionsproteine
|
GB0611405D0
(en)
*
|
2006-06-09 |
2006-07-19 |
Univ Belfast |
FKBP-L: A novel inhibitor of angiogenesis
|
AU2007278994B2
(en)
|
2006-07-24 |
2013-08-15 |
Biorexis Pharmaceutical Corporation |
Exendin fusion proteins
|
TW200817438A
(en)
*
|
2006-08-17 |
2008-04-16 |
Hoffmann La Roche |
A conjugate of an antibody against CCR5 and an antifusogenic peptide
|
BRPI0715660B8
(pt)
|
2006-09-01 |
2021-05-25 |
Zymogenetics Inc |
anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
|
EP2354254A1
(de)
|
2006-09-06 |
2011-08-10 |
Ortho-McNeil Pharmaceutical, Inc. |
Biomarker zur Überprüfung der Reaktion auf eine C-Met-Behandlung
|
AU2007292903B2
(en)
|
2006-09-08 |
2012-03-29 |
Ambrx, Inc. |
Modified human plasma polypeptide or Fc scaffolds and their uses
|
EP2114437A2
(de)
*
|
2006-10-16 |
2009-11-11 |
ConjuChem Biotechnologies Inc. |
Modifizierte peptide mit corticotropinfreisetzungsfaktor und verwendungen davon
|
US8268347B1
(en)
|
2006-10-24 |
2012-09-18 |
Aradigm Corporation |
Dual action, inhaled formulations providing both an immediate and sustained release profile
|
WO2008052043A2
(en)
*
|
2006-10-24 |
2008-05-02 |
Cogenesys, Inc. |
Opioid receptor agonist fusion proteins
|
US7825093B2
(en)
|
2006-10-25 |
2010-11-02 |
Amgen Inc. |
Methods of using OSK1 peptide analogs
|
US20100173367A1
(en)
*
|
2006-10-27 |
2010-07-08 |
Marner Ii Wesley D |
Functionalized molecules comprising an autosilification moiety and methods of making and using same
|
CA2667637C
(en)
|
2006-10-31 |
2021-04-20 |
East Carolina University |
Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
|
WO2008056961A1
(en)
*
|
2006-11-10 |
2008-05-15 |
Boryung Pharmaceutical Co., Ltd |
A novel fusion protein, cell lines expressing the same and preparation method thereof
|
EP2120998B1
(de)
|
2006-11-28 |
2013-08-07 |
HanAll Biopharma Co., Ltd. |
Modifizierte erythropoetin-polypeptide und ihre verwendungen zur behandlung
|
WO2008077616A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Csl Behring Gmbh |
Modified coagulation factors with prolonged in vivo half-life
|
US20090099074A1
(en)
*
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
US20090088378A1
(en)
*
|
2007-01-12 |
2009-04-02 |
Omar Quraishi |
Long lasting inhibitors of viral infection
|
AU2008211227B2
(en)
|
2007-01-30 |
2014-04-17 |
Epivax, Inc. |
Regulatory T cell epitopes, compositions and uses thereof
|
HUP0700203A2
(en)
*
|
2007-03-08 |
2008-12-29 |
Univ Szegedi |
Sustained release, core-shell structure precipitated citokine bionanocomposit, a process for producing the same and use thereof
|
EP2136832B1
(de)
|
2007-03-26 |
2015-09-02 |
General Regeneratives Limited |
Verfahren zur förderung des schutzes und der regeneration von knochenmark mit cxcl9 und anti-cxcl9-antikörpern
|
BRPI0809583B1
(pt)
|
2007-03-30 |
2022-02-22 |
Ambrx, Inc |
Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
|
UA100692C2
(ru)
|
2007-05-02 |
2013-01-25 |
Мериал Лимитед |
Днк-плазмиды, имеющие повышенную экспрессию и стабильность
|
WO2008137471A2
(en)
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
EP2703011A3
(de)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
AU2008255027B2
(en)
|
2007-05-14 |
2013-10-03 |
Astrazeneca Ab |
Methods of reducing eosinophil levels
|
JP2010527376A
(ja)
*
|
2007-05-16 |
2010-08-12 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
抗ウイルスペプチドのシステイン酸誘導体
|
EP2738257A1
(de)
*
|
2007-05-22 |
2014-06-04 |
Amgen Inc. |
Zusammensetzungen und Verfahren zur Herstellung bioaktiver Fusionsproteine
|
WO2008150495A2
(en)
*
|
2007-06-01 |
2008-12-11 |
Archemix Corp. |
Vwf aptamer formulations and methods for use
|
EP1997830A1
(de)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
WO2008157824A2
(en)
*
|
2007-06-21 |
2008-12-24 |
Conjuchem Biotechnologies Inc. |
Thrombopoietin peptide conjugates
|
AR067536A1
(es)
*
|
2007-07-17 |
2009-10-14 |
Hoffmann La Roche |
Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
|
AR067537A1
(es)
*
|
2007-07-17 |
2009-10-14 |
Hoffmann La Roche |
Purificacion de polipeptidos pegilados
|
CL2008002092A1
(es)
|
2007-07-20 |
2009-05-29 |
Hoffmann La Roche |
Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
|
WO2009012600A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Novagen Holding Corporation |
Fusion proteins
|
WO2009023549A2
(en)
*
|
2007-08-09 |
2009-02-19 |
University Of Rochester |
Vaccine against botulism
|
US8933197B2
(en)
*
|
2007-08-15 |
2015-01-13 |
Amunix Operating Inc. |
Compositions comprising modified biologically active polypeptides
|
RU2015147300A
(ru)
|
2007-08-29 |
2019-01-11 |
Санофи-Авентис |
Гуманизированные антитела к cxcr5, их производные и их применение
|
CA2698343C
(en)
|
2007-09-04 |
2018-06-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
WO2009045553A1
(en)
*
|
2007-10-05 |
2009-04-09 |
Barofold, Inc. |
High pressure treatment of aggregated interferons
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
US8946148B2
(en)
|
2007-11-20 |
2015-02-03 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
WO2009070642A1
(en)
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
JP5744522B2
(ja)
|
2007-12-07 |
2015-07-08 |
ザイモジェネティクス, インコーポレイテッド |
Il−31に特異的なヒト化抗体分子
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
MX343594B
(es)
|
2007-12-21 |
2016-11-11 |
Medimmune Ltd |
Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
|
WO2009082485A1
(en)
|
2007-12-26 |
2009-07-02 |
Vaccinex, Inc. |
Anti-c35 antibody combination therapies and methods
|
WO2009118300A1
(en)
|
2008-03-25 |
2009-10-01 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
CN102014625A
(zh)
|
2008-04-28 |
2011-04-13 |
佐吉尼克斯股份有限公司 |
用于治疗偏头痛的新制剂
|
JP6192891B2
(ja)
|
2008-05-02 |
2017-09-06 |
ノバルティス アーゲー |
改善されたフィブロネクチンベースの結合分子およびそれらの使用
|
ES2531464T3
(es)
|
2008-06-24 |
2015-03-16 |
Csl Behring Gmbh |
Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
|
WO2010014909A1
(en)
*
|
2008-08-01 |
2010-02-04 |
Syntonix Pharmaceuticals, Inc. |
Immunomodulatory peptides
|
EP2815766B1
(de)
|
2008-08-05 |
2017-07-05 |
Novartis AG |
Zusammensetzungen und Verfahren für auf das Komplementprotein C5 gerichtete Antikörper
|
US8163497B2
(en)
|
2008-09-07 |
2012-04-24 |
Glyconex Inc. |
Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
|
KR20110093775A
(ko)
*
|
2008-11-03 |
2011-08-18 |
바이엘 헬스케어 엘엘씨 |
혈우병 치료 방법
|
EP2358392B1
(de)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antikörper-formulierung
|
CN102282168A
(zh)
*
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
WO2010078325A2
(en)
|
2008-12-29 |
2010-07-08 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides for reducing or preventing restenosis
|
JP5753095B2
(ja)
*
|
2009-01-16 |
2015-07-22 |
テバ ファーマシューティカル インダストリーズ リミテッド |
組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
NZ628987A
(en)
|
2009-02-03 |
2015-11-27 |
Amunix Operating Inc |
Extended recombinant polypeptides and compositions comprising same
|
DK2396347T3
(en)
|
2009-02-11 |
2017-07-24 |
Albumedix As |
ALBUMIN VARIANTS AND CONJUGATES
|
EP2398504B1
(de)
|
2009-02-17 |
2018-11-28 |
Cornell Research Foundation, Inc. |
Verfahren und Kits zur Diagnose von Krebs und Vorhersage des therapeutischen Nutzens
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
EP3348275A3
(de)
|
2009-03-31 |
2018-10-24 |
East Carolina University |
Cytokine und neuroantigene zur behandlung von immunerkrankungen
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
KR101183262B1
(ko)
|
2009-04-22 |
2012-09-14 |
(주)알테오젠 |
체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법
|
EP2427486B1
(de)
|
2009-05-07 |
2015-02-25 |
Novozymes Biopharma DK A/S |
Verfahren zur Aufreinigung von Albumin
|
WO2010138555A2
(en)
|
2009-05-26 |
2010-12-02 |
University Of Florida Research Foundation, Inc. |
Small peptide expression system in mammalian cells
|
US20120108514A1
(en)
|
2009-07-09 |
2012-05-03 |
University Of Iowa Research Foundation |
Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
|
US8945895B2
(en)
*
|
2009-07-31 |
2015-02-03 |
Baxter International Inc. |
Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
|
CA2769822C
(en)
|
2009-08-13 |
2019-02-19 |
The Johns Hopkins University |
Methods of modulating immune function
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
US8451450B2
(en)
*
|
2009-09-14 |
2013-05-28 |
Bio-Rad Laboratories, Inc. |
Near real time optical phase conjugation
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
DK2486141T3
(en)
|
2009-10-07 |
2018-04-23 |
Macrogenics Inc |
FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
NZ598465A
(en)
|
2009-10-30 |
2013-10-25 |
Boehringer Ingelheim Int |
Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
|
BR112012009450A2
(pt)
|
2009-10-30 |
2017-05-23 |
Novozymes Biopharma Dk As |
variantes de albumina
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
EP2502939B1
(de)
|
2009-11-19 |
2016-01-27 |
Zhejiang University |
Unnatürliches collagen-artiges protein und seine verwendung
|
BR112012012526A2
(pt)
*
|
2009-11-24 |
2016-05-03 |
Syngenta Participations Ag |
misturas estáveis e métodos relacionados
|
CA3040276A1
(en)
|
2009-12-02 |
2011-06-09 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
PT2506868T
(pt)
|
2009-12-06 |
2018-02-23 |
Bioverativ Therapeutics Inc |
Polipéptidos quiméricos e hibridos de factor viii-fc, e métodos de utilização dos mesmos
|
ES2654102T3
(es)
|
2010-01-19 |
2018-02-12 |
Hanmi Science Co., Ltd. |
Formulaciones líquidas para conjugado de C-CSF de acción prolongada
|
WO2011092233A1
(en)
|
2010-01-29 |
2011-08-04 |
Novartis Ag |
Yeast mating to produce high-affinity combinations of fibronectin-based binders
|
US20130004519A1
(en)
|
2010-03-05 |
2013-01-03 |
Ruth Chiquet-Ehrismann |
Smoci, tenascin-c and brain cancers
|
CN102939304B
(zh)
|
2010-04-09 |
2017-04-19 |
阿尔布麦狄克斯公司 |
白蛋白衍生物和变体
|
GB201105584D0
(en)
|
2011-04-01 |
2011-05-18 |
Imp Innovations Ltd |
Cancer methods
|
WO2011131611A1
(en)
|
2010-04-19 |
2011-10-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
US9290573B2
(en)
|
2010-05-06 |
2016-03-22 |
Novartis Ag |
Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
AU2011249783B9
(en)
|
2010-05-06 |
2014-11-06 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (LRP6) antibodies
|
US20130089538A1
(en)
|
2010-06-10 |
2013-04-11 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
CA2803093A1
(en)
|
2010-06-24 |
2011-12-29 |
Panmed Ltd. |
Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
|
DK2585098T3
(da)
|
2010-06-28 |
2014-11-03 |
Five Prime Therapeutics Inc |
Ekstracellulære FZD8-domæner og fusionsmolekyler fraekstracellulære FZD8-domæner til anvendelse ved behandling afobesitet og obesitet-relaterede lidelser
|
TW201217526A
(en)
|
2010-07-09 |
2012-05-01 |
Biogen Idec Hemophilia Inc |
Chimeric clotting factors
|
MY192639A
(en)
|
2010-07-09 |
2022-08-29 |
Bioverativ Therapeutics Inc |
Factor ix polypeptides and methods of use thereof
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
BR112013003522B1
(pt)
|
2010-08-17 |
2021-05-25 |
Ambrx, Inc. |
polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
|
DK2606070T3
(en)
|
2010-08-20 |
2017-03-27 |
Novartis Ag |
Antibodies for the epidermal growth factor receptor 3 (HER3)
|
KR20140018837A
(ko)
|
2010-08-27 |
2014-02-13 |
스템 센트알엑스 인코포레이티드 |
노텀 단백질 조절 인자 및 사용 방법
|
US9458231B2
(en)
|
2010-09-03 |
2016-10-04 |
Stemcentrx, Inc. |
Modulators and methods of use
|
US20130171159A1
(en)
|
2010-09-10 |
2013-07-04 |
Brian Arthur Hemmings |
Phosphorylated twist1 and metastasis
|
JP5735650B2
(ja)
|
2010-09-14 |
2015-06-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Peg化エリスロポエチンを精製するための方法
|
DK2635607T3
(da)
|
2010-11-05 |
2019-11-18 |
Zymeworks Inc |
Stabilt heterodimert antistofdesign med mutationer i fc-domænet
|
EP2640738A1
(de)
|
2010-11-15 |
2013-09-25 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Antimykotische wirkstoffe
|
KR20130124513A
(ko)
|
2010-11-15 |
2013-11-14 |
파이브 프라임 테라퓨틱스, 인크. |
가용성 fgfr1 융합 단백질의 상승된 투약량에 의한 암 치료
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
US8911734B2
(en)
|
2010-12-01 |
2014-12-16 |
Alderbio Holdings Llc |
Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
|
TWI585106B
(zh)
|
2010-12-08 |
2017-06-01 |
艾伯維史坦森特瑞斯有限責任公司 |
新穎調節劑及其使用方法
|
US20120171195A1
(en)
|
2011-01-03 |
2012-07-05 |
Ravindranath Mepur H |
Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
|
EP2663578A2
(de)
|
2011-01-14 |
2013-11-20 |
Five Prime Therapeutics, Inc. |
Il-27 antagonisten zur behandlung von entzündungserkrankungen
|
CA2824143C
(en)
|
2011-01-14 |
2018-12-18 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
WO2012116453A1
(en)
|
2011-03-03 |
2012-09-07 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
JP2014510730A
(ja)
|
2011-03-16 |
2014-05-01 |
サノフイ |
デュアルv領域抗体様タンパク質の使用
|
CA2836799C
(en)
|
2011-05-20 |
2021-05-18 |
Alderbio Holdings Llc |
Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
|
US9708393B2
(en)
|
2011-05-20 |
2017-07-18 |
Alderbio Holdings Llc |
Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
|
EP3662932B1
(de)
|
2011-05-20 |
2021-04-07 |
H. Lundbeck A/S |
Anti-cgrp-zusammensetzungen und verwendung davon
|
US9181553B2
(en)
|
2011-06-06 |
2015-11-10 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Method of treatment of breast cancers over-expressing the SHP2 signature genes
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
PL2717898T3
(pl)
|
2011-06-10 |
2019-06-28 |
Bioverativ Therapeutics Inc. |
Związki o działaniu prokoagulacyjnym i sposoby ich stosowania
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
JP2014522641A
(ja)
|
2011-07-01 |
2014-09-08 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
リラキシン融合ポリペプチドおよびその使用
|
EP2729492B1
(de)
|
2011-07-05 |
2019-01-02 |
Albumedix Ltd |
Albuminformulierung und verwendung
|
WO2013007563A1
(en)
|
2011-07-08 |
2013-01-17 |
Bayer Intellectual Property Gmbh |
Fusion proteins releasing relaxin and uses thereof
|
EP3513804B1
(de)
|
2011-07-08 |
2022-03-23 |
Bioverativ Therapeutics Inc. |
Chimäre und hybride faktor-viii-polypeptide und verfahren zur verwendung davon
|
US10656167B2
(en)
|
2011-07-25 |
2020-05-19 |
Bioverativ Therapeutics Inc. |
Assays to monitor bleeding disorders
|
EP2751136B1
(de)
|
2011-08-30 |
2017-10-18 |
Mayo Foundation For Medical Education And Research |
Natriuretische polypeptide
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
KR102132997B1
(ko)
|
2011-10-11 |
2020-07-14 |
메디뮨 엘엘씨 |
Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
AU2012332588B2
(en)
|
2011-11-01 |
2017-09-07 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
JP2014533247A
(ja)
|
2011-11-01 |
2014-12-11 |
バイオノミクス インコーポレイテッド |
抗体および癌を治療する方法
|
WO2013067060A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
JP2015502741A
(ja)
|
2011-11-04 |
2015-01-29 |
ノバルティス アーゲー |
低比重リポタンパク質関連タンパク質6(lrp6)−半減期延長構築物
|
ES2899956T3
(es)
|
2011-11-04 |
2022-03-15 |
Zymeworks Inc |
Diseño de anticuerpo heterodimérico estable con mutaciones en el dominio Fc
|
WO2013068431A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
US20140294732A1
(en)
|
2011-11-08 |
2014-10-02 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Early diagnostic of neurodegenerative diseases
|
EP2780364A2
(de)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteine mit verbesserter halbwertzeit und anderen eigenschaften
|
EA029602B1
(ru)
|
2011-11-29 |
2018-04-30 |
Проклара Байосайенсиз, Инк. |
Применение белков р3 бактериофага в качестве агентов, связывающих амилоид
|
CN108341873B
(zh)
|
2011-12-05 |
2022-03-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
EA201491107A1
(ru)
|
2011-12-05 |
2014-11-28 |
Новартис Аг |
Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
|
BR112014015111A2
(pt)
|
2011-12-21 |
2017-06-13 |
Novartis Ag |
composições e processos para anticorpos que se direcionam ao fator p
|
EP2800583A1
(de)
|
2012-01-02 |
2014-11-12 |
Novartis AG |
Cdcp1 und brustkrebs
|
WO2013103896A1
(en)
|
2012-01-06 |
2013-07-11 |
Mayo Foundation For Medical Education And Research |
Treating cardiovascular or renal diseases
|
US10800847B2
(en)
|
2012-01-11 |
2020-10-13 |
Dr. Mepur Ravindranath |
Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
EP2817338B1
(de)
|
2012-02-24 |
2017-07-26 |
AbbVie Stemcentrx LLC |
Dll3-modulatoren und verwendungsverfahren
|
JP2015509980A
(ja)
|
2012-03-14 |
2015-04-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Hcv−hiv同時感染患者集団のhcv感染症を治療するための併用療法
|
KR20140136934A
(ko)
|
2012-03-16 |
2014-12-01 |
노보자임스 바이오파마 디케이 에이/에스 |
알부민 변이체
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
CA2862516C
(en)
|
2012-03-27 |
2023-02-14 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods of use for treating metabolic disorders
|
WO2013143581A1
(en)
|
2012-03-28 |
2013-10-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in specific patient subgenotype sub-population
|
US20150266961A1
(en)
|
2012-03-29 |
2015-09-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute |
Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
|
US10064951B2
(en)
|
2012-03-30 |
2018-09-04 |
Hanmi Science Co., Ltd. |
Liquid formulation of highly concentrated long-acting human growth hormone conjugate
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
AU2013258834B2
(en)
|
2012-05-10 |
2017-09-07 |
Zymeworks Bc Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
|
KR20220051197A
(ko)
|
2012-05-17 |
2022-04-26 |
익스텐드 바이오사이언시즈, 인크. |
개선된 약물 전달용 캐리어
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
US20130323221A1
(en)
|
2012-05-30 |
2013-12-05 |
Biostrategies LC |
Plant lectins as carriers of associated drug substances into animal and human cells
|
EP2857417B1
(de)
|
2012-06-05 |
2018-02-14 |
CJ Healthcare Corporation |
Hochglykosyliertes hgh-protein und herstellungsverfahren dafür
|
EP2866831A1
(de)
|
2012-06-29 |
2015-05-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krankheiten durch modulation einer spezifischen isoform von mkl1
|
US10656156B2
(en)
|
2012-07-05 |
2020-05-19 |
Mepur Ravindranath |
Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
|
US20150184154A1
(en)
|
2012-07-05 |
2015-07-02 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
New treatment for neurodegenerative diseases
|
WO2014008480A2
(en)
|
2012-07-06 |
2014-01-09 |
Biogen Idec Ma Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
AU2013289881B2
(en)
|
2012-07-13 |
2018-01-18 |
Zymeworks Bc Inc. |
Multivalent heteromultimer scaffold design and constructs
|
AR091902A1
(es)
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
WO2014036520A1
(en)
|
2012-08-30 |
2014-03-06 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
DK2892547T3
(da)
|
2012-09-10 |
2020-10-26 |
Xencor Inc |
Dominant, negativ tnf-alpha-hæmmer til anvendelse i behandling af neurologiske cns-forstyrrelser
|
TWI810729B
(zh)
|
2012-09-25 |
2023-08-01 |
美商百歐維拉提夫治療公司 |
Fix多肽的應用
|
EA033666B1
(ru)
|
2012-10-02 |
2019-11-14 |
Proclara Biosciences Inc |
Амилоидсвязывающие белки и их применение
|
WO2014070953A1
(en)
|
2012-10-30 |
2014-05-08 |
Biogen Idec Ma Inc. |
Methods of Using FVIII Polypeptide
|
KR20150082422A
(ko)
|
2012-11-08 |
2015-07-15 |
노보자임스 바이오파마 디케이 에이/에스 |
알부민 변이체
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
SG11201503567SA
(en)
|
2012-12-05 |
2015-06-29 |
Novartis Ag |
Compositions and methods for antibodies targeting epo
|
BR112015018104A2
(pt)
|
2013-01-30 |
2017-11-21 |
Ngm Biopharmaceuticals Inc |
polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
|
US9161966B2
(en)
|
2013-01-30 |
2015-10-20 |
Ngm Biopharmaceuticals, Inc. |
GDF15 mutein polypeptides
|
WO2014122605A1
(en)
|
2013-02-08 |
2014-08-14 |
Friedrich Miescher Institute For Biomedical Research |
Novel methods for the targeted introduction of viruses into cells
|
DK2956160T3
(en)
|
2013-02-15 |
2018-08-06 |
Mayo Found Medical Education & Res |
INSULIN SECRETING POLYPEPTIDE
|
CA2901226C
(en)
|
2013-02-18 |
2020-11-17 |
Vegenics Pty Limited |
Vascular endothelial growth factor binding proteins
|
USRE48805E1
(en)
*
|
2013-03-06 |
2021-11-02 |
Vision Global Holdings Ltd. |
Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
|
US9255262B2
(en)
*
|
2013-03-06 |
2016-02-09 |
Vision Global Holdings Ltd. |
Albumin-binding arginine deminase and the use thereof
|
CA2940513C
(en)
|
2013-03-11 |
2023-08-15 |
University Of Florida Research Foundation, Inc. |
Delivery of card protein as therapy for ocular inflammation
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
US9623088B2
(en)
|
2013-03-15 |
2017-04-18 |
Bioverativ Therapeutics Inc. |
Factor VIII polypeptide formulations
|
AU2014228938B2
(en)
|
2013-03-15 |
2019-05-02 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
WO2014147489A2
(en)
|
2013-03-15 |
2014-09-25 |
Teva Pharmaceutical Industries Ltd. |
Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia in pediatric patients
|
JP6505079B2
(ja)
|
2013-03-29 |
2019-04-24 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
補体c5を標的とする治療薬の血清半減期を増加させるための組成物及び方法
|
CN106913865A
(zh)
|
2013-04-18 |
2017-07-04 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素‑10治疗疾病和病症的方法
|
EP2796145B1
(de)
|
2013-04-22 |
2017-11-01 |
CSL Ltd. |
Ein kovalenter komplex bestehend aus von willebrand und faktor viii verbunden mit einer disulfidbrücke
|
CN105188732A
(zh)
|
2013-05-01 |
2015-12-23 |
戊瑞治疗有限公司 |
治疗癌症的方法
|
KR20160013092A
(ko)
|
2013-05-23 |
2016-02-03 |
파이브 프라임 테라퓨틱스, 인크. |
암을 치료하는 방법
|
AU2014274253B2
(en)
|
2013-05-28 |
2018-06-14 |
Proclara Biosciences, Inc. |
Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
|
CA2914837A1
(en)
|
2013-06-17 |
2014-12-24 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
ES2911690T3
(es)
|
2013-07-03 |
2022-05-20 |
H Lundbeck As |
Regulación del metabolismo de la glucosa mediante anticuerpos anti-CGRP
|
US20160178610A1
(en)
|
2013-08-07 |
2016-06-23 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment Friedreich's ataxia
|
CA2922547C
(en)
|
2013-08-28 |
2020-03-10 |
Stemcentrx, Inc. |
Site-specific antibody conjugation methods and compositions
|
WO2015031541A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Novel sez6 modulators and methods of use
|
WO2015031316A1
(en)
|
2013-08-30 |
2015-03-05 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
DK3063275T3
(da)
|
2013-10-31 |
2019-11-25 |
Resolve Therapeutics Llc |
Terapeutiske nuklease-albumin-fusioner og fremgangsmåder
|
JP6660297B2
(ja)
|
2013-11-11 |
2020-03-11 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
疾患及び障害を処置するためのインターロイキン−10の使用方法
|
US10325687B2
(en)
|
2013-12-06 |
2019-06-18 |
Bioverativ Therapeutics Inc. |
Population pharmacokinetics tools and uses thereof
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
MA39779A
(fr)
|
2014-03-24 |
2017-02-01 |
Biogen Ma Inc |
Formulations de facteur ix lyophilisées
|
AU2015240599B2
(en)
|
2014-04-04 |
2020-11-19 |
Bionomics, Inc. |
Humanized antibodies that bind LGR5
|
EP3137098A4
(de)
|
2014-04-29 |
2017-11-01 |
Mayo Foundation for Medical Education and Research |
Butyrylcholinesterasen mit verbesserter fähigkeit zur hydrolyse von acyl-ghrelin
|
RU2016144908A
(ru)
|
2014-05-02 |
2018-06-05 |
Серени Терапеутикс Холдинг Са |
Маркеры hdl-терапии
|
US10293043B2
(en)
|
2014-06-02 |
2019-05-21 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
DK3173420T3
(da)
*
|
2014-07-23 |
2021-10-18 |
Nat Ct Nanoscience & Technology China |
Polypeptid og polypeptidkompleks til undertrykkelse af tumormetastase og behandling af leukæmi samt fremgangsmåde til fremstilling deraf og anvendelse deraf
|
MD20170020A2
(ro)
|
2014-07-30 |
2017-07-31 |
Ngm Biopharmaceuticals, Inc. |
Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
DK3177642T3
(da)
|
2014-08-07 |
2022-02-21 |
Novartis Ag |
Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
|
US10166273B2
(en)
|
2014-08-12 |
2019-01-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein
|
US20170216403A1
(en)
|
2014-08-12 |
2017-08-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
WO2016046768A1
(en)
|
2014-09-24 |
2016-03-31 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
CA2909044A1
(en)
*
|
2014-10-10 |
2016-04-10 |
Queen's University At Kingston |
Rhomboid proteins and uses thereof
|
EP3206713A4
(de)
|
2014-10-14 |
2018-06-27 |
Armo Biosciences, Inc. |
Interleukin-15-zusammensetzungen und verwendungen davon
|
EP3220961B1
(de)
|
2014-10-22 |
2023-07-05 |
Extend Biosciences, Inc. |
Therapeutische vitamin-d-konjugate
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
ES2941234T3
(es)
|
2014-10-22 |
2023-05-19 |
Armo Biosciences Inc |
Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
|
US9616109B2
(en)
|
2014-10-22 |
2017-04-11 |
Extend Biosciences, Inc. |
Insulin vitamin D conjugates
|
JP6949711B2
(ja)
|
2014-10-23 |
2021-10-20 |
エヌジーエム バイオファーマシューティカルス,インコーポレーテッド |
ペプチドバリアントを含む医薬組成物及びその使用方法
|
US9434778B2
(en)
|
2014-10-24 |
2016-09-06 |
Bristol-Myers Squibb Company |
Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
|
NZ730054A
(en)
|
2014-10-31 |
2023-11-24 |
Ngm Biopharmaceuticals Inc |
Compositions and methods of use for treating metabolic disorders
|
RU2730668C2
(ru)
|
2014-11-19 |
2020-08-24 |
Аксон Ньюросайенс Се |
Гуманизированные тау-антитела при болезни альцгеймера
|
KR20170085132A
(ko)
|
2014-12-03 |
2017-07-21 |
프로클라라 바이오사이언시즈, 인크. |
글리코실화 신호가 결핍된 변형된 박테리오파지 g3p 아미노산 서열을 포함하는 폴리펩티드
|
KR20170084332A
(ko)
*
|
2014-12-04 |
2017-07-19 |
노파르티스 아게 |
Klotho 변이체 폴리펩티드를 사용하는 방법 및 조성물
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
EP3233916A4
(de)
|
2014-12-19 |
2018-06-06 |
Alder Biopharmaceuticals, Inc. |
Humanisierte anti-acth-antikörper und verwendungen davon
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
AU2016228806B2
(en)
*
|
2015-03-12 |
2020-10-22 |
Medimmune, Llc |
Method of purifying albumin-fusion proteins
|
CA3176123A1
(en)
|
2015-05-19 |
2016-11-24 |
Yale University |
Compositions for treating pathological calcification conditions, and methods using same
|
JP7121496B2
(ja)
|
2015-05-28 |
2022-08-18 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
癌治療で使用するためのペグ化インターロイキン-10
|
CA2986774A1
(en)
|
2015-05-29 |
2016-12-08 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
EA201792561A1
(ru)
|
2015-06-05 |
2018-04-30 |
Новартис Аг |
Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
|
US10519207B2
(en)
|
2015-06-12 |
2019-12-31 |
Georgia State University Research Foundation, Inc. |
Compositions and methods for treating opioid tolerance
|
DK3307296T3
(da)
|
2015-06-15 |
2021-12-13 |
Univ Leland Stanford Junior |
Timp2 til anvendelse til behandling af aldringsassocierede tilstande
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
JP6940479B2
(ja)
|
2015-08-03 |
2021-09-29 |
ノバルティス アーゲー |
Fgf21関連障害を処置する方法
|
CA2994951A1
(en)
|
2015-08-07 |
2017-02-16 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
JP2018528191A
(ja)
|
2015-08-19 |
2018-09-27 |
ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー |
抗体を生成する新規な方法
|
CA2989966A1
(en)
|
2015-08-20 |
2017-02-23 |
Albumedix A/S |
Albumin variants and conjugates
|
AU2016312510A1
(en)
|
2015-08-25 |
2018-03-08 |
Armo Biosciences, Inc. |
Methods of using Interleukin-10 for treating diseases and disorders
|
EP3348635B1
(de)
|
2015-09-08 |
2021-02-17 |
JCR Pharmaceuticals CO., LTD. |
Neuartiger mutant von humanem serumalbumin
|
EA038332B1
(ru)
|
2015-09-09 |
2021-08-10 |
Новартис Аг |
Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
|
SI3347377T1
(sl)
|
2015-09-09 |
2021-06-30 |
Novartis Ag |
Protitelesa, ki vežejo timusni stromalni limfopoietin (tslp) in postopki uporabe protiteles
|
EP3355910A4
(de)
|
2015-09-28 |
2019-08-28 |
East Carolina University |
Auf aluminium basierte adjuvanzien für tolerogene impfung
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
EP3888672A1
(de)
|
2015-11-09 |
2021-10-06 |
NGM Biopharmaceuticals, Inc. |
Verfahren zur behandlung von gallensäurebedingten erkrankungen
|
KR20180089510A
(ko)
|
2015-12-18 |
2018-08-08 |
노파르티스 아게 |
CD32b를 표적화하는 항체 및 그의 사용 방법
|
EP3402819A1
(de)
|
2016-01-11 |
2018-11-21 |
Novartis AG |
Immunstimulierende humanisierte monoklonale antikörper gegen menschliches interleukin-2 und fusionsproteine davon
|
EP3405492B1
(de)
|
2016-01-21 |
2020-10-21 |
Novartis AG |
Gegen cll-1 gerichtete multispezifische moleküle
|
EP3431508A4
(de)
|
2016-03-14 |
2019-08-14 |
JCR Pharmaceuticals Co., Ltd. |
Serumalbumin-20-k-wachstumshormonfusionprotein
|
AU2017239038A1
(en)
|
2016-03-22 |
2018-10-04 |
Bionomics Inc |
Administration of an anti-LGR5 monoclonal antibody
|
AU2017241161B2
(en)
|
2016-03-31 |
2022-05-26 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
CN109451728A
(zh)
|
2016-04-15 |
2019-03-08 |
奥尔德生物制药公司 |
抗pacap抗体及其用途
|
CN109414481B
(zh)
|
2016-04-25 |
2022-11-01 |
葛兰素史克知识产权开发有限公司 |
用于治疗病理性肌肉损失和虚弱的nope
|
JP2019515677A
(ja)
|
2016-04-26 |
2019-06-13 |
アール.ピー.シェーラー テクノロジーズ エルエルシー |
抗体複合体ならびにそれを作製および使用する方法
|
JP7138567B2
(ja)
|
2016-04-27 |
2022-09-16 |
ノバルティス アーゲー |
成長分化因子15に対する抗体およびそれらの使用
|
BR112018073669A2
(pt)
*
|
2016-05-20 |
2019-02-26 |
Octapharma Ag |
proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso
|
AU2017283787B2
(en)
|
2016-06-15 |
2020-09-17 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
CA3027143A1
(en)
|
2016-07-15 |
2018-01-18 |
F. Hoffmann-La Roche Ag |
Method for purifying pegylated erythropoietin
|
WO2018053216A1
(en)
|
2016-09-15 |
2018-03-22 |
Mayo Foundation For Medical Education And Research |
Methods and materials for using butyrylcholinesterases to treat cancer
|
US11072642B2
(en)
|
2016-11-09 |
2021-07-27 |
Mayo Foundation For Medical Education And Research |
MANP analogues
|
KR20190099256A
(ko)
|
2016-12-23 |
2019-08-26 |
노파르티스 아게 |
항-인자 XI/XIa 항체를 사용한 치료 방법
|
IL267538B1
(en)
|
2016-12-23 |
2024-01-01 |
Novartis Ag |
Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
|
EP3568150A4
(de)
|
2017-01-10 |
2020-12-02 |
Xcella Biosciences, Inc. |
Kombinationstumorbehandlung mit integrin-bindendem fc-fusionsprotein und immunmodulator
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
MX2019009498A
(es)
|
2017-02-08 |
2019-10-02 |
Novartis Ag |
Anticuerpos mimeticos de fgf21 y usos de los mismos.
|
JP2020507350A
(ja)
*
|
2017-02-10 |
2020-03-12 |
ヴィヴィババ インコーポレイテッド |
組換え神経成長因子のための組成物及び方法
|
MA50141A
(fr)
*
|
2017-04-20 |
2020-07-29 |
Novo Nordisk As |
Procédés de purification de protéines de fusion d'albumine
|
KR102637960B1
(ko)
|
2017-04-22 |
2024-02-21 |
이뮤노믹 쎄라퓨틱스, 인크. |
개선된 lamp 구축물
|
JP7222915B2
(ja)
|
2017-05-02 |
2023-02-15 |
イミュノミック セラピューティックス, インコーポレイテッド |
癌抗原を含む改善されたlamp構築物
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2019036605A2
(en)
|
2017-08-17 |
2019-02-21 |
Massachusetts Institute Of Technology |
MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
|
WO2019035001A1
(en)
|
2017-08-18 |
2019-02-21 |
Friedrich Miescher Institute For Biomedical Research |
NEW METHODS FOR TARGETED INTRODUCTION OF VIRUSES IN CELLS AND TISSUES
|
CN111315767A
(zh)
|
2017-08-22 |
2020-06-19 |
萨纳生物有限责任公司 |
可溶性干扰素受体及其用途
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
WO2019094268A1
(en)
|
2017-11-10 |
2019-05-16 |
Armo Biosciences, Inc. |
Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors
|
CA3083345A1
(en)
|
2017-11-27 |
2019-05-31 |
Purdue Pharma L.P. |
Humanized antibodies targeting human tissue factor
|
JP2021513570A
(ja)
|
2018-02-12 |
2021-05-27 |
バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーBiontech Rna Pharmaceuticals Gmbh |
サイトカインをコードするrnaを用いた治療
|
WO2019186344A1
(en)
|
2018-03-28 |
2019-10-03 |
Institut Pasteur De Tunis |
Anti-cancer and disintegrin scorpion venoms
|
EP3774877A1
(de)
*
|
2018-03-28 |
2021-02-17 |
Bioxodes |
Antikoagulierende fusionsproteine und verwendungen davon
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
CN112384531A
(zh)
|
2018-06-01 |
2021-02-19 |
诺华股份有限公司 |
针对bcma的结合分子及其用途
|
EP3810189A1
(de)
|
2018-06-19 |
2021-04-28 |
Armo Biosciences, Inc. |
Zusammensetzungen und verfahren zur verwendung von il-10-wirkstoffen in verbindung mit einer chimären antigen-rezeptor-zelltherapie
|
WO2020020783A1
(en)
|
2018-07-24 |
2020-01-30 |
Biontech Rna Pharmaceuticals Gmbh |
Il2 agonists
|
CN110818793A
(zh)
*
|
2018-08-14 |
2020-02-21 |
中山康方生物医药有限公司 |
抗IL-1β的抗体、其药物组合物及其用途
|
US20200102370A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020109978A1
(en)
|
2018-11-26 |
2020-06-04 |
Novartis Ag |
Lpl-gpihbp1 fusion polypeptides
|
SG11202106686PA
(en)
|
2019-01-04 |
2021-07-29 |
Resolve Therapeutics Llc |
Treatment of sjogren's disease with nuclease fusion proteins
|
US11235032B2
(en)
|
2019-01-23 |
2022-02-01 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
JP2022519713A
(ja)
|
2019-02-08 |
2022-03-24 |
バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー |
Car操作されたt細胞およびサイトカインを含む治療
|
SG11202108857SA
(en)
|
2019-03-18 |
2021-09-29 |
Biontech Cell & Gene Therapies Gmbh |
Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
|
US20220169706A1
(en)
|
2019-03-28 |
2022-06-02 |
Danisco Us Inc |
Engineered antibodies
|
WO2020200481A1
(en)
|
2019-04-05 |
2020-10-08 |
Biontech Rna Pharmaceuticals Gmbh |
Treatment involving interleukin-2 (il2) and interferon (ifn)
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
TW202100559A
(zh)
|
2019-05-21 |
2021-01-01 |
瑞士商諾華公司 |
Cd19 結合分子及其用途
|
US11827671B2
(en)
|
2019-05-24 |
2023-11-28 |
Sanofi |
Methods for treating systemic sclerosis
|
TW202115105A
(zh)
|
2019-06-24 |
2021-04-16 |
德商拜恩迪克Rna製藥有限公司 |
Il2激動劑
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質-金属水酸化物錯体およびその方法
|
EP4031578A1
(de)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2-antikörper, kombinationstherapien und verfahren zur verwendung der antikörper und kombinationstherapien
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
WO2021058091A1
(en)
|
2019-09-24 |
2021-04-01 |
Biontech Rna Pharmaceuticals Gmbh |
Treatment involving therapeutic antibody and interleukin-2 (il2)
|
KR20220083773A
(ko)
|
2019-10-18 |
2022-06-20 |
이뮤노믹 쎄라퓨틱스, 인크. |
암 항원을 포함하는 개선된 lamp 구축물
|
EP4069200A1
(de)
|
2019-12-04 |
2022-10-12 |
Albumedix Ltd |
Verfahren und damit hergestellte zusammensetzungen
|
WO2021129927A1
(en)
|
2019-12-23 |
2021-07-01 |
Biontech Cell & Gene Therapies Gmbh |
Treatment with immune effector cells engineered to express an antigen receptor
|
JP2023512423A
(ja)
*
|
2019-12-24 |
2023-03-27 |
ジュベナ・セラピューティクス・インコーポレイテッド |
再生性ポリペプチドおよびその使用
|
WO2021129945A1
(en)
|
2019-12-27 |
2021-07-01 |
Biontech Cell & Gene Therapies Gmbh |
In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins)
|
MX2022008772A
(es)
|
2020-01-14 |
2022-10-07 |
Synthekine Inc |
Ortologos de il2 y metodos de uso.
|
JP2023518935A
(ja)
|
2020-03-16 |
2023-05-09 |
バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー |
抗原特異的t細胞受容体およびt細胞エピトープ
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
WO2021197589A1
(en)
|
2020-03-31 |
2021-10-07 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination
|
SG10202003296VA
(en)
|
2020-04-06 |
2021-11-29 |
H Lundbeck As |
Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
US20230272089A1
(en)
|
2020-08-05 |
2023-08-31 |
Synthekine, Inc |
Il2rg binding molecules and methods of use
|
JP2023536654A
(ja)
|
2020-08-05 |
2023-08-28 |
シンセカイン インコーポレイテッド |
IL10Ra結合分子および使用方法
|
JP2023538533A
(ja)
|
2020-08-07 |
2023-09-08 |
ブリストル-マイヤーズ スクイブ カンパニー |
線維症の処置のための、ccr2/5拮抗剤と組み合わせたfgf21
|
JP2023540082A
(ja)
|
2020-09-04 |
2023-09-21 |
ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー |
SARS-CoV-2ワクチン及び抗体
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
WO2022115597A1
(en)
|
2020-11-25 |
2022-06-02 |
Bristol-Myers Squibb Company |
Methods of treating liver diseases
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
CN117321076A
(zh)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
中和SARS-CoV-2的单结构域抗体
|
WO2022218891A2
(en)
|
2021-04-12 |
2022-10-20 |
BioNTech SE |
Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
|
EP4326317A1
(de)
|
2021-04-20 |
2024-02-28 |
BioNTech SE |
Virusimpfstoff
|
AU2022333323A1
(en)
|
2021-08-27 |
2024-02-29 |
H. Lundbeck A/S |
Treatment of cluster headache using anti-cgrp antibodies
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
WO2023066496A1
(en)
|
2021-10-21 |
2023-04-27 |
BioNTech SE |
Coronavirus vaccine
|
WO2023067193A2
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Compositions for administration of different doses of rna
|
WO2023083434A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
|
WO2023126053A1
(en)
|
2021-12-28 |
2023-07-06 |
BioNTech SE |
Lipid-based formulations for administration of rna
|
WO2023165681A1
(en)
|
2022-03-01 |
2023-09-07 |
BioNTech SE |
Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer
|
WO2023193892A1
(en)
|
2022-04-05 |
2023-10-12 |
BioNTech SE |
Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
|
TW202400658A
(zh)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
靶向il—13和il—18的多特異性抗體
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024017479A1
(en)
|
2022-07-21 |
2024-01-25 |
BioNTech SE |
Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
|
WO2024028325A1
(en)
|
2022-08-01 |
2024-02-08 |
BioNTech SE |
Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
|
WO2024027910A1
(en)
|
2022-08-03 |
2024-02-08 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
WO2024028445A1
(en)
|
2022-08-03 |
2024-02-08 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
US11773160B1
(en)
|
2022-08-05 |
2023-10-03 |
Anaveon AG |
Immune-stimulating IL-2 fusion proteins
|